Hap Trading, LLC Metacrine, Inc. Call Options Transaction History

Hap Trading, LLC

  • $872 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$0.36 - $0.63 $8,496 - $14,868
-23,600 Reduced 61.3%
14,900 $0
Q1 2022

May 12, 2022
BUY
$0.43 - $0.7 $11,051 - $17,990
25,700 Added 200.78%
38,500 $4,000
Q4 2021

Feb 14, 2022
BUY
$0.64 - $3.83 $8,192 - $49,024
12,800 New
12,800 $1,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email